Clinical Research Veterinarian IDEXX Batesburg, South Carolina, United States
Abstract:
Background: Cancer Dx uses a multi-omics platform to detect lymphoma in canine blood. Retrospective data suggest it can detect lymphoma in clinically well dogs > 3 months before clinical diagnosis.
Objective: Evaluate the utility of Cancer Dx to screen for lymphoma in dogs, and report interim study results and outcomes for dogs with at least 3 months of follow-up.
Animals: 2,977 dogs at increased cancer risk due to age and/or breed, presenting for wellness visits at general practices in the USA and Canada between April 1 and November 30, 2025, with complete study data available.
Methods: Prospective observational study. At enrollment, dogs had a physical examination, CBC, biochemistry, and Cancer Dx testing. For results consistent with lymphoma (i.e. positive), diagnostic workups were optional but incentivized. Clinics completed outcome surveys for enrolled dogs 3 and 6 months later. Data analyzed include Cancer Dx results, diagnostic workup findings when available, follow-up duration, and outcome classification at 3 months.
Results: Cancer Dx positivity rate was 0.78%. Seventeen dogs (74%) had some form of diagnostic workup following a positive test result; of those 29% were definitively diagnosed with lymphoproliferative neoplasia and 24% had a presumptive diagnosis of neoplasia. 1,343 dogs had 3-month outcome surveys completed; median follow-up time for all cases was 91 days. No dogs with negative results had a reported diagnosis of lymphoproliferative neoplasia during the follow-up period.
Conclusions and Clinical Importance: Cancer Dx can detect lymphoma prior to development of clinical signs in dogs at increased cancer risk during wellness visits.
